Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of a range of oral doses of
COL-144 in treating migraine headache, in order to select a dose or doses for further
evaluation.
Phase:
Phase 2
Details
Lead Sponsor:
CoLucid Pharmaceuticals Eli Lilly and Company
Collaborators:
CoLucid Pharmaceuticals FGK Clinical Research GmbH